Health Novo Nordisk’s Weight-Loss Drug Offers New Hope for Alzheimer’s Treatment Biogen Inc. CEO Chris Viehbacher has indicated that a successful Alzheimer’s trial for Novo Nordisk A/S’s weight-loss drug could not only complement his company’s... Editorial16 hours ago